Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76829
Title:
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
Authors:
Thistlethwaite, Fiona C ( 0000-0002-4832-7008 ) ; Mansoor, Was; Gilham, David E; Hawkins, Robert E
Abstract:
The combination of power and specificity inherent within the immune system make its manipulation an attractive prospect for the development of novel anticancer therapies. However, tumors are frequently poorly recognized by the immune system, and intrinsic controls limit the benefit from active immunization. These and other issues have proved major challenges in the search for effective cancer immunotherapy. Recent advances in the understanding of the immune system and the development of methods to manipulate it have led to the point where engineered T-cell therapy can be tested in the clinical setting with a realistic chance of success. These advances are considered and potential future clinical and scientific issues involved in the successful development of effective, engineered T-cell therapy are examined.
Affiliation:
Cancer Research UK, Department of Medical Oncology, Christie Research Centre, Manchester, UK.
Citation:
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. 2005, 7 (1):48-55 Curr. Opin. Mol. Ther.
Journal:
Current Opinion in Molecular Therapeutics
Issue Date:
Feb-2005
URI:
http://hdl.handle.net/10541/76829
PubMed ID:
15732529
Type:
Article
Language:
en
ISSN:
1464-8431
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorThistlethwaite, Fiona C-
dc.contributor.authorMansoor, Was-
dc.contributor.authorGilham, David E-
dc.contributor.authorHawkins, Robert E-
dc.date.accessioned2009-08-10T17:14:01Z-
dc.date.available2009-08-10T17:14:01Z-
dc.date.issued2005-02-
dc.identifier.citationEngineering T-cells with antibody-based chimeric receptors for effective cancer therapy. 2005, 7 (1):48-55 Curr. Opin. Mol. Ther.en
dc.identifier.issn1464-8431-
dc.identifier.pmid15732529-
dc.identifier.urihttp://hdl.handle.net/10541/76829-
dc.description.abstractThe combination of power and specificity inherent within the immune system make its manipulation an attractive prospect for the development of novel anticancer therapies. However, tumors are frequently poorly recognized by the immune system, and intrinsic controls limit the benefit from active immunization. These and other issues have proved major challenges in the search for effective cancer immunotherapy. Recent advances in the understanding of the immune system and the development of methods to manipulate it have led to the point where engineered T-cell therapy can be tested in the clinical setting with a realistic chance of success. These advances are considered and potential future clinical and scientific issues involved in the successful development of effective, engineered T-cell therapy are examined.en
dc.language.isoenen
dc.subject.meshCell Proliferation-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshProtein Engineering-
dc.subject.meshReceptors, Antigen, T-Cell-
dc.subject.meshRecombinant Fusion Proteins-
dc.subject.meshSignal Transduction-
dc.subject.meshT-Lymphocytes-
dc.titleEngineering T-cells with antibody-based chimeric receptors for effective cancer therapy.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Department of Medical Oncology, Christie Research Centre, Manchester, UK.en
dc.identifier.journalCurrent Opinion in Molecular Therapeuticsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.